| University | University College London (UCL) |
|---|---|
| Subject | Bispecific Antibodies |
Bispecific Antibodies in Myeloma Treatment Pathways
Bispecifc antibodies are the latest in a long line of novel-acting therapies in myeloma.
Should they be restricted to last-line use after existing therapies, e.g. immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 antibody or should they be used in combing earlier in the pathway?
Hint you will need to show an understanding of future indications and current clinical trials.
Do You Need Assignment of This Question
Finding assignments on Bispecific Antibodies in myeloma challenging? Diploma Assignment Help UK offers cheap assignment help that is human-written and plagiarism-free. Check our oncology assignment help or haematology assignment help for reliable, expert guidance to achieve top grades
